Bioactivity and Cellular Assays

Custom-tailored assay design to assess the functionality of your drug candidate

Adequate bioassays are needed during all stages of drug development, e.g. for candidate screening, characterization of potential modes of action and safety assessment during preclinical testing as well as potency, stability and comparability testing during manufacturing.

FyoniBio provides bioanalytical services applying its long-term expertise in the development of functional and potency bioassays for different biotherapeutics (e.g. antibodies and glycoproteins). Our team is used to work with a number of complex cell-based assays using different target and effector cells including human primary immune cells. The portfolio comprises methods to assess target and effector cell binding, signaling events, viability, cytotoxicity, cytokine release and other immune functions. Assay validation and application within clinical trials is our daily business.

FyoniBio is certified according to ISO 9001 and complies with the current bioanalytical guidelines of ICH, FDA and EMA.

Our Core Competencies

Binding assays

  • Target binding
  • Fc receptor binding
  • Dual cell binding
  • Blood cell binding
  • Internalization

Cell viability and cytotoxicity

  • ADCC with different effector cells
  • CDC
  • Viability
  • Proliferation assays (2D or 3D culture)
  • Apoptosis detection
  • Phagocytosis
  • Cell cycle analysis


  • Isolation, differentiation and phenotyping of immune cell populations
  • T cell activation
  • T cell proliferation
  • Immune checkpoint assays (e.g. Mixed lymphocyte reactions)


  • Receptor modulation & phosphorylation
  • cAMP release assay

Cytokine release testing

  • Whole blood assays
  • PBMC-HUVEC co-culture assay
  • PBMC high/low density pre-culture


  • Coagulation assays for blood factors
  • Enzymatic activity assays (e.g. Enzyme replacement therapy)
  • Custom-specific assay development

Technologies available

  • multicolor flow cytometry,
  • imaging,
  • immunohistochemistry, immunofluorescence,
  • Alpha technology and
  • electrochemiluminescence (ECL)
Dr. Doreen Weigelt


Bioactivity and cellular assays
(1 MB)